Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- Grifols Biologicals, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT03091751
- Locations
- 🇧🇬
Medical University Pleven, Pleven, Bulgaria
🇧🇬National Center of Haematology, Sofia, Bulgaria
🇧🇬Medical University, University Hospital "Sveta Marina",, Varna, Bulgaria
Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries
Phase 3
Completed
- Conditions
- Soft Tissue Surgical Bleeding
- Interventions
- Biological: Fibrin Sealant (FS) GrifolsDevice: Surgicel®
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Grifols Biologicals, LLC
- Target Recruit Count
- 327
- Registration Number
- NCT01731938
- Locations
- 🇺🇸
404, Bridgeport, Connecticut, United States
🇺🇸407, Florence, Alabama, United States
🇺🇸320, 322, 323, Pasadena, California, United States
Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
Phase 4
Active, not recruiting
- Conditions
- Von Willebrand Disease
- Interventions
- Biological: Alphanate SD/HT
- First Posted Date
- 2007-11-08
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Grifols Biologicals, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00555555
IGIV Study for Chronic ITP Patients Ages 3-70
Phase 3
Completed
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Biological: IGIV3I Grifols 10%
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- Grifols Biologicals, LLC
- Target Recruit Count
- 64
- Registration Number
- NCT00511147
- Locations
- 🇺🇸
Kenmar Research Institute, LLC, Los Angeles, California, United States
🇺🇸Western Pennsylvannia Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Arizona Oncology Associates, Tucson, Arizona, United States
Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Grifols Biologicals, LLC
- Target Recruit Count
- 51
- Registration Number
- NCT00323856
- Locations
- 🇵🇱
Oddzial Chorob Wewnetrznych i Hematologii, Poznan, Szkolna, Poland
🇵🇱Katedra i Klinika Hematologii Collegium Medicum UJ, Krakow, Poland
Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate
Phase 2
Active, not recruiting
- Conditions
- Antithrombin III Deficiency
- Interventions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Grifols Biologicals, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00319228
© Copyright 2025. All Rights Reserved by MedPath